Biontech SE
BNTX105.890USD
+3.870+3.79%
Horário de mercado （ET）Cotações atrasadas em 15 min
25.41BValor de mercado
PerdaP/L TTM
Mais detalhes de Biontech SE Empresa
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Informações da empresa
Código da empresaBNTX
Nome da EmpresaBiontech SE
Data de listagemOct 10, 2019
Fundado em2019
CEOProf. Ugur Sahin, M.D.
Número de funcionários6772
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 10
EndereçoAn der Goldgrube 12
CidadeMAINZ
Bolsa de valoresNASDAQ Global Select Consolidated
PaísGermany
Código postal55131
Telefone4949613190840
Sitehttps://www.biontech.com/
Código da empresaBNTX
Data de listagemOct 10, 2019
Fundado em2019
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Detalhamento da receita
Moeda: EURTempo de atualização: qua, 12 de mar
Moeda: EURTempo de atualização: qua, 12 de mar
FY2019
FY2018
FY2017
Por EmpresaEUR
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Sem dados
Por Empresa
Por Região
Por EmpresaEUR
Nome
Receita
Proporção
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Acionista
Tempo de atualização: qui, 13 de mar
Tempo de atualização: qui, 13 de mar
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Estatísticas dos acionistas
Acionista
Proporção
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Tipo
Acionista
Proporção
Corporation
60.82%
Investment Advisor
15.74%
Investment Advisor/Hedge Fund
3.45%
Individual Investor
2.41%
Hedge Fund
0.93%
Sovereign Wealth Fund
0.75%
Research Firm
0.65%
Pension Fund
0.21%
Bank and Trust
0.18%
Other
14.86%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
822
205.15M
85.49%
+3.95M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
2022Q4
937
198.79M
81.74%
-3.98M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
AT Impf GmbH
101.85M
42.44%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.43M
16.85%
-7.37K
-0.02%
Dec 31, 2024
Baillie Gifford & Co.
8.22M
3.43%
-87.49K
-1.05%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.45M
2.69%
+1.27M
+24.48%
Dec 31, 2024
Flossbach von Storch AG
4.41M
1.84%
+47.24K
+1.08%
Dec 31, 2024
PRIMECAP Management Company
4.30M
1.79%
-220.70K
-4.89%
Dec 31, 2024
Pfizer Inc
3.66M
1.52%
+3.66M
--
Dec 31, 2024
Sahin (Ugur MD)
2.77M
1.16%
+1.92M
+224.09%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Dec 31, 2024
Wolfgang (Jeggle Helmut)
1.43M
0.59%
-100.00K
-6.55%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Global X Genomics & Biotechnology ETF
4.75%
Langar Global HealthTech ETF
4.42%
iShares Genomics Immunology and Healthcare ETF
4.13%
First Trust NYSE Arca Biotechnology Index Fund
2.86%
Franklin Genomic Advancements ETF
2.33%
VanEck Biotech ETF
2.2%
Range Cancer Immunotherapy ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.51%
iShares Biotechnology ETF
1.38%
First Trust International Equity Opportunities ETF
1.33%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção4.75%
Langar Global HealthTech ETF
Proporção4.42%
iShares Genomics Immunology and Healthcare ETF
Proporção4.13%
First Trust NYSE Arca Biotechnology Index Fund
Proporção2.86%
Franklin Genomic Advancements ETF
Proporção2.33%
VanEck Biotech ETF
Proporção2.2%
Range Cancer Immunotherapy ETF
Proporção1.61%
Virtus LifeSci Biotech Products ETF
Proporção1.51%
iShares Biotechnology ETF
Proporção1.38%
First Trust International Equity Opportunities ETF
Proporção1.33%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados